Skip to Content

Verde Science Inc VRCI

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

VRCI is trading at a 35% premium.
Price
$0.00
Fair Value
$5.78
Uncertainty
Extreme
1-Star Price
$8.97
5-Star Price
Economic Moat
Xzcj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VRCI is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
/
Market Cap
$23.87
Volume/Avg
3,000 / 283,817

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Verde Science Inc operates as a pharmaceutical research and development company, engages in the development of pharmaceutical drugs utilizing cannabis resin. The company is focused on the discovery of drugs and treatment modalities, as well as diagnostic devices and pharmaceutical delivery systems for the treatment of diseases and medical issues. It is focused on developing medicinal formulations from cannabinoids and tetrahydrocannabinol (THC) compounds for the treatment of various issues, such as migraines, glaucoma, loss of appetite from cancer therapies, and other medical issues.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
2

Valuation

Metric
VRCI
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
VRCI

Financial Strength

Metric
VRCI
Quick Ratio
0.00
Current Ratio
0.01
Interest Coverage
−2.42
Quick Ratio
VRCI

Profitability

Metric
VRCI
Return on Assets (Normalized)
−11,468.11%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
VRCI
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FzbmqlbxfDwmpn$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
MwmlgjysPmnjz$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
FvndbyvfLhnspl$117.2 Bil
Moderna Inc
MRNA
MwwtchblpWpxs$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
YgkwtclGwclf$30.1 Bil
argenx SE ADR
ARGX
CpvhhmlkRxg$28.0 Bil
BioNTech SE ADR
BNTX
RxwspnqmMfry$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
WvwbrxwkMtmlnkh$16.0 Bil
United Therapeutics Corp
UTHR
WvkgxypTzlz$14.6 Bil
Incyte Corp
INCY
StmyyttzRscgyb$13.0 Bil

Sponsor Center